What is HC Wainwright's Estimate for APLS FY2028 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $2.35 for the year, down from their prior estimate of $2.61. HC Wainwright currently has a "Buy" rating and a $57.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals' FY2029 earnings at $3.84 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million during the quarter, compared to analysts' expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business's revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.73) earnings per share.

Other equities research analysts have also recently issued research reports about the stock. Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 target price for the company. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Monday. Royal Bank of Canada decreased their target price on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday. JPMorgan Chase & Co. lifted their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, Robert W. Baird reduced their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.53.

Remove Ads

Apellis Pharmaceuticals Stock Performance

APLS traded down $0.28 during trading on Tuesday, hitting $25.04. The stock had a trading volume of 1,520,174 shares, compared to its average volume of 1,920,320. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company has a 50 day moving average price of $29.23 and a 200-day moving average price of $31.22. Apellis Pharmaceuticals has a one year low of $23.77 and a one year high of $63.40. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of -12.33 and a beta of 0.93.

Insider Activity at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares of the company's stock, valued at $3,482,123. This trade represents a 3.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the transaction, the chief accounting officer now owns 48,138 shares in the company, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,934 shares of company stock valued at $1,950,261 in the last quarter. Insiders own 6.80% of the company's stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC increased its stake in Apellis Pharmaceuticals by 10.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock valued at $390,011,000 after purchasing an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. increased its position in Apellis Pharmaceuticals by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company's stock valued at $320,569,000 after buying an additional 230,450 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company's stock worth $112,036,000 after buying an additional 735,160 shares during the period. Braidwell LP grew its stake in Apellis Pharmaceuticals by 410.8% in the third quarter. Braidwell LP now owns 3,125,183 shares of the company's stock valued at $90,130,000 after acquiring an additional 2,513,383 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock valued at $88,084,000 after acquiring an additional 939,289 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).